RARA CRAFT DATABASE for FDA Medical Devices
510(k)K233895

FDA DEVICE FACTS

EZ Glide Aortic Perfusion Cannulae (EZC21A, EZC21TA, EZC24A, EZC24TA, EZF21A, EZF21TA, EZF24A, EZF24TA, EZS21A, EZS21TA, EZS24A and EZS24TA); OptiSite Arterial Perfusion Cannulae (OPTI16, OPTI18, OPTI20 and OPTI22); EndoReturn Arterial Cannulae (ER21B and ER23B);

Edwards Lifesciences

FDA-sourced product information for medical-device development research. Use the official FDA sources at the end of this page when the original public document wording is needed.医療機器開発の調査用に、FDA の公開情報から取った製品情報を示しています。公開文書の原文が必要なときは、このページの最後にある FDA の公式な出典をご覧ください。

DECISION DATEFebruary 5, 2024PRODUCT CODEDWF

Indications for use

EZ Glide Aortic Perfusion Cannulae: Aortic perfusion cannulae are intended for perfusion of the aorta during short-term (≤6 hours) cardiopulmonary bypass procedures. Aortic perfusion cannulae may be used in pediatric or adult populations based on the flow rate requirements and individual patient anatomy. Please consult labeling to determine pressure drop related to flow rates. OptiSite Arterial Perfusion Cannulae: The Edwards Lifesciences arterial perfusion cannulae are indicated for arterial perfusion in the extracorporeal circuit for < 6 hours. Cannulation site selection is left to the discretion of the surgeon and may include the femoral artery or the aortic arch.

EndoReturn Arterial Cannulae: The EndoReturn arterial cannula are indicated for patients undergoing cardiopulmonary bypass. They are intended to deliver oxygenated blood for cardiopulmonary bypass during surgery. The EndoReturn arterial cannula with hemostasis valve also allows the hemostatic introduction and removal of vascular catheters such as the EndoClamp aortic catheter. Indications for Use Comparison

Predicate and Substantial Equivalence Device Information, Indications for Use comparison, EZ Glide Aortic Perfusion Cannulae The subject EZ Glide Aortic Perfusion Cannulae is substantially equivalent to the EZ Glide Aortic Perfusion Cannulae device cleared in in K123370 on March 13, 2013. There is no substantial change to Indications for Use, since Edwards no longer manufacture cannulae with the Duraflo coating, no change in design and no change in manufacturing between the predicate and subject device.

Predicate device Indications for Use: Aortic perfusion cannulae are intended for perfusion of the aorta during short-term (≤6 hours) cardiopulmonary bypass procedures. Aortic perfusion cannulae may be used in pediatric or adult populations based on the flow rate requirements and individual patient anatomy. Please consult labeling to determine pressure drop related to flow rates. Extracorporeal circuit components with a Duraflo coating are intended for use in cardiopulmonary surgery when a heparin coated blood path is desired.

Subject device Indications for Use: Aortic perfusion cannulae are intended for perfusion of the aorta during short-term (≤6 hours) cardiopulmonary bypass procedures. Aortic perfusion cannulae may be used in pediatric or adult populations based on the flow rate requirements and individual patient anatomy. Please consult labeling to determine pressure drop related to flow rates.

Predicate and Substantial Equivalence Device Information, Indications for Use comparison, OptiSite Arterial Perfusion Cannulae The subject OptiSite Arterial Perfusion Cannuale is substantially equivalent to the OptiSite Arterial Perfusion Cannulae device cleared in K073559 on January 24, 2008. There is no substantial change to Indications for Use, no change in design and no change in manufacturing between the predicate and subject device.

Predicate device Indications for Use: The Edwards Lifesciences Arterial Perfusion Cannula is indicated for arterial perfusion in the extracorporeal circuit for <6 hours. Cannulation site selection is left to the discretion of the surgeon and may include the femoral artery or the aortic arch. Subject device Indications for Use: The Edwards Lifesciences arterial perfusion cannulae are indicated for arterial perfusion in the extracorporeal circuit for < 6 hours. Cannulation site selection is left to the discretion of the surgeon and may include the femoral artery or the aortic arch.

Predicate and Substantial Equivalence Device Information, Indications for Use comparison, EndoReturn Arterial Cannulae The subject EndoReturn Arterial Cannulae is substantially equivalent to the EndoReturn Arterial Cannulae device cleared in K971291 on June 17, 1997. There is no substantial change to Indications for Use, no change in design and no change in manufacturing between the predicate and subject device.

Predicate device Indications for Use: The Endoarterial Return Cannula, with or without hemostasis valve, is indicated for patients undergoing cardiopulmonary bypass. It is intended to deliver oxygenated blood for cardiopulmonary bypass during surgery. The Endoarterial Return Cannula with hemostasis valve also allows the hemostatic introduction and removal of vascular catheters such as the HeartportTM Endoaortic ClampTM Catheter.

Subject device Indications for Use: The EndoReturn arterial cannula are indicated for patients undergoing cardiopulmonary bypass. They are intended to deliver oxygenated blood for cardiopulmonary bypass during surgery. The EndoReturn arterial cannula with hemostasis valve also allows the hemostatic introduction and removal of vascular catheters such as the EndoClamp aortic catheter.

See the full product information製品情報をすべて見るには

Device description, AI/software, PCCP, evaluation and limitations are available with an account: seven days of full access after free registration, then with the paid plan.機器の説明、AI・ソフトウェア、PCCP、評価、制限事項は、アカウントでご覧いただけます。無料登録から 7 日間はすべて利用でき、その後は有料プランでご利用いただけます。

Start free 7-day access7日間無料で利用するLog inログイン

OFFICIAL FDA SOURCES

FDA Record and Public Document Status

Record and document link states are stored separately.FDA Record と公開文書のリンクの状態は、別々に記録しています。

Information reviewed:情報の確認日: August 17, 2026